Biophytis has FAMHP Approval to conduct SARA-INT phase 2b Interventional Study of Sarconeos in Sarcopenia in Belgium
December 04, 2017 01:45 ET
|
BIOPHYTIS SA
PARIS, Dec. 04, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, today...
BIOPHYTIS Completes a €7.5 M Capital Increase to Help Accelerate Pipeline Programs in Orphan Pediatric Diseases
November 01, 2017 02:45 ET
|
BIOPHYTIS SA
PARIS, Nov. 01, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company focused on innovative therapeutics to restore the muscular and visual functions in diseases...
BIOPHYTIS Has FDA Approval to Initiate SARA-INT Phase 2b Interventional Study of Sarconeos in Sarcopenia
October 30, 2017 01:45 ET
|
BIOPHYTIS SA
PARIS, Oct. 30, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris: ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, today...
Biophytis Appoints Professor Thomas Voit to Scientific Advisory Board to Help Accelerate Pipeline Programs in Orphan Pediatric Diseases
October 27, 2017 01:45 ET
|
BIOPHYTIS SA
PARIS, France, Oct. 27, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company focused on innovative therapeutics to restore the muscular and visual functions in...
BIOPHYTIS: Half-Year Financial Report as of June 30, 2017
October 26, 2017 12:00 ET
|
BIOPHYTIS SA
PARIS, Oct. 26, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, presents...
BIOPHYTIS completes a €10.4 M capital increase to finance mid-stage clinical trials for two novel anti-aging drug-candidates
October 11, 2017 06:28 ET
|
BIOPHYTIS SA
PARIS, Oct. 11, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, announces...
BIOPHYTIS filed IND application for approval by FDA of SARA-INT Phase 2b study of Sarconeos in Sarcopenia
September 25, 2017 08:00 ET
|
BIOPHYTIS SA
Protocol has been adjusted according to EMA Scientific AdviceFiling in Europe will be done in the coming days PARIS, Sept. 25, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a...
Biophytis Clinical Stage Drug-Candidate Sarconeos Demonstrates Efficacy in Preclinical Models of Duchenne Muscular Dystrophy
September 08, 2017 08:00 ET
|
BIOPHYTIS SA
Biophytis announces abstract accepted at World Muscle Society international congress (3-7 October 2017, St Malo, France)Duchenne muscular dystrophy is a new Orphan indication for Sarconeos PARIS,...
BIOPHYTIS selects SGS Life Science Services to conduct MACA-PK, clinical study of Macuneos in dry AMD
June 16, 2017 12:02 ET
|
BIOPHYTIS SA
PARIS, June 16, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, has announced...
BIOPHYTIS: First patient-in in the United States and opening of 2 clinical centers for the SARA-OBS study on Sarcopenia
May 11, 2017 08:00 ET
|
BIOPHYTIS SA
PARIS, May 11, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specialized in the development of drug candidates to treat ageing diseases, has announced that it...